Experience with iohexol in lumbar myelography.
An open phase II clinical trial of iohexol for lumbar myelography in 17 patients is reported. The overall frequency of adverse reactions was exceedingly low. Special attention was paid to psychic reactions and no such were recorded. The CSF analyses and EEG recordings before and after myelography did not differ significantly. The CSF protein content could not be evaluated as the contrast medium interfered with the reagents.
D000328:Adult; D000368:Aged; D002555:Cerebrospinal Fluid / Q000032:analysis; D003287:Contrast Media / Q000009:adverse effects; D004341:Drug Evaluation; D004569:Electroencephalography; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007405:Intervertebral Disc Displacement / Q000000981:diagnostic imaging; D007463:Iodobenzoates; D007472:Iohexol; D008161:Lumbosacral Region; D008297:Male; D008875:Middle Aged; D009192:Myelography / Q000379:methods*; D013130:Spinal Stenosis / Q000000981:diagnostic imaging; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol